CLINICAL GUIDELINES FOR RED BLOOD CELL TRANSFUSION

Adherence to proper indications for red blood cells (RBC) transfusion is essential because of its potential adverse effects and costs of therapy. Aim of these recommendations is to summarize typed of RBC concentrates and indications for RBC transfusions among different categories of the patients. Methods. The methodological approaches are based on the recommendations of the Russian expert council (leading specialists of the Russian Federation) and literature search for randomized clinical trials evaluating RBC storage duration, hemoglobin thresholds and clinical indications for RBC transfusion without language restrictions. Results. The draft clinical guidelines were reviewed on February 1, 2018 at First Russian Transfusiology Congress of the (Vladivostok). The main types of RBC concentrates, storage duration, transport conditions and indications for RBC transfusions are presented. The indications for RBC transfusions are analyzed for various clinical conditions (in obstetrics, neonatology, hematology, cardiology, neurosurgery, nephrology, in patients with sepsis and septic shock, patients with acute blood loss, in patients after hematopoietic stem cell and organ transplantation). Conclusion. The recommendations are intended for doctors of various specialties, health administrators, medical students.

1. Постановление Правительства РФ от 26 января 2010 г. №29 «Об утверждении технического регламента о требованиях безопасности крови, ее продуктов, кровезамещающих растворов и технических средств, используемых в трансфузионно-инфузионной терапии».

2. Жибурт ЕБ, Протопопова ЕБ, Губанова МН, Каюмова ЛИ, Кузьмин НС, Танкаева ХС. Циркуляторная перегрузка — «новое» осложнение переливания крови. Трансфузиология. 2016;1775—89.

3. Афонин АН, Мороз ВВ, Карпун НА. Острое повреждение легких, ассоциированное с трансфузионной терапией. Общая реаниматология. 2009;2:70—5.

4. Остальные источники см. в References

5. Bennett-Guerrero E, Veldman TH, Doctor A et al. Evolution of adverse changes in stored RBCs. Proc Nat Acad Sci USA. 2007;104:17063—68.

6. Reynolds JD, Hess DT, Stamler JS. The transfusion problem: role of aberrant S-nitrosylation. Transfusion. 2011;51:852—8.

7. Baek JH, D’Agnillo F, Vallelian F, Pereira CP, Williams MC, Jia Y et al. Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. J Clin Invest. 2012;122:1444—58. Таблица 4 (окончание). Реакции и осложнения, возникающие у реципиентов при переливании ЭСК (этиология, диагностика, лечение) Table 4 (ending). Adverse reactions and complications after red blood cell transfusions (etiology, diagnosis, treatment) Вид реакций и осложнений Type of reactions and complications Причина Cause Лечебные мероприятия Treatment Обязательные и дополнительные лабораторные и инструментальные исследования реципиента Mandatory and additional laboratory and instrumental tests Септический шок Septic shock Трансфузия (переливание) инфицированного ЭСК Transfusion of bacterial contaminated RBC Терапия антибиотиками широкого спектра действия и противошоковая терапия Broad-spectrum antibiotic therapy and anti-shock therapy Обязательные исследования: бактериологическое исследование крови больного и ЭСК Mandatory tests: blood culture Перегрузка железом — гемохроматоз Iron overload — hemochromatosis Многократные переливания эритроцитов Multiple red blood cell transfusions Препараты группы комплексообразующих средств (деферазирокс 15—20 мг/кг или другой препарат с аналогичным действием) Iron chelators (deferasirox 15—20 mg/kg) Обязательные исследования: ферритин сыворотки более 1000 нг/мл Mandatory tests: ferritin measurement (reference: over 1000 ng/ml)

8. Kriebardis AG, Antonelou MH, Stamoulis KE, Economou-Petersen E, Margaritis LH, Papassideri IS. RBC-derived vesicles during storage: Ultrastructure, protein composition, oxidation, and signaling components. Transfusion. 2008;48:1943—53. 5. Cardo LJ, Hmel P, Wilder D. Stored packed red blood cells contain a procoagulant phospholipid reducible by leukodepletion filters and washing. Transfus Apher Sci. 2008;38:141—7.

9. Sweeney J, Kouttab N, Kurtis J. Stored red blood cell supernatant facilitates thrombin generation. Transfusion. 2009;49:1569—79.

10. Silliman CC, Clay KL, Thurman GW, Johnson CA, Ambruso DR. Partial characterization of lipids that develop during the routine storage of blood and prime the neutrophil NADPH oxidase. J Lab Clin Med. 1994;124:684—94.

11. Blajchman MA. Immunomodulation and blood transfusion. Am J Ther. 2002;9:389—95.

12. Blumberg N. Deleterious clinical effects of transfusion immunomodulation: Proven beyond a reasonable doubt. Transfusion. 2005;45:33S—39S.

13. Luten M, Roerdinkholder-Stoelwinder B, Bos HJ, Bosman GJ. Survival of the fittest? — Survival of stored red blood cells after transfusion. Cell Mol Biol. 2004;50:197—203.

14. Zeiler T, Muller JT, Kretschmer V. Flow-cytometric determination of survival time and 24-hour recovery of transfused red blood cells. Transfus Med Hemother. 2003;30:14—9.

15. Luten M, Roerdinkholder-Stoelwinder B, Schaap NP, de Grip WJ, Bos HJ, Bosman GJ. Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods. Transfusion. 2008;48:1478—85.

16. Creteur J, Neves AP, Vincent JL.Near-infrared spectroscopy technique to evaluate the effects of red blood cell transfusion on tissue oxygenation. Crit Care. 2009;13 Suppl 5:S11.

17. Guide to the preparation, use and quality assurance of blood components : recommendation No. R (95) 15. European Directorate for the Quality of Medicines & Healthcare (EDQM). Strasbourg. 2017. 540 р.

18. Prowse CV, de Korte D, Hess JR, van der Meer PF; Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Commercially available blood storage containers. Vox Sang. 2014;106:1—13.

19. D’Alessandro A, Reisz JA, Culp-Hill R, Korsten H, van Bruggen R, de Korte D. Metabolic effect of alkaline additives and guanosine/gluconate in storage solutions for red blood cells. Transfusion. 2018;58:1992—2002.

20. Zehnder L, Schulzki T, Goede JS, Hayes J, Reinhart WH. Erythrocyte storage in hypertonic (SAGM) or isotonic (PAGGSM) conservation medium: influence on cell properties. Vox Sang. 2008;95:280—7.

21. Approval of technical regulations on safety of blood, its products, blood substitutes and the technical facilities used in transfusion and infusion therapy (with changes of October 12, 2010): The resolution of the Government of the Russian Federation of January 26, 2010, No. 29 (in Russian).

22. Politis C, Wiersum JC, Richardson C, Robillard P, Jorgensen J, Renaudier P et al. The international haemovigilance network database for the surveillance of adverse reactions and events in donors and recipients of blood components: technical issues and results. Vox Sang. 2016;111:409—17.

23. Buch J., Sachs UJH. Pulmonary transfusion reactions. Transfus Med Hemother. 2008;35:337—45.

24. Zhiburt EB, Protopopova EB, Gubanova MN, Kayumova LI, Kuzmin NS, Tankaeva HS. Transfusion-associated circulatory overload — «new» adverse effect of blood transfusion. Transfusiology. 2016;17:75—89 (in Russian).

25. Afonin AN, Moroz VV, Karpun NA. Acute transfusion-associated lung injury. General Reanimatology. 2009;2:70—5 (in Russian).

26. Приказ № 183н от 2 апреля 2013 г. «Об утверждении правил клинического использования донорской крови и/или ее компонентов» МЗ РФ.

27. Коноводова ЕН, Серов ВН, Бурлев ВА, Тютюнник ВЛ, Кан НЕ, Протопопова ТА и др. Диагностика, профилактика и лечение железодефицитных состояний у беременных и родильниц. Акушерство и гинекология. 2012;4/2:3—9.

28. Остальные источники см. в References.

29. References

30. The order No. 183n “On validation of regulations of clinical use of donor blood and(or) Its components” of the Ministry of Health of Russia (in Russian).

31. Guidelines for the administration of blood products. Australian and New Zealand Society of Blood Transfusion Ltd. Royal College of Nursing, Australia. 2nd edition. December 2011. 104 p.

32. Prevention and management of postpartum haemorrhage. RCOG Green-top Guideline, 2007. No. 52.

33. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. Anesthesiology. 2015;122:241—75.

34. Wise A, Clark V. Strategies to manage major obstetric haemorrhage. Curr Opin Anaesthesiol. 2008;21:281—7.

35. National Institute for Health and Care Excellence (NICE). 2015. Available at: http://www.nice.org.uk/guidance/indevelopment/gidCGWAVE0663

36. Kotze A, Harris A, Baker C, Iqbal T, Lavies N, Richards T et al. British Committee for Standards in Haematology guidelines on the identification and management of pre-operative anaemia. Br J Haematol. 2015;171:322—31. doi: 10.1111/bjh.13623

37. Network for the Advancement of Patient Blood Management, Haemоstasis and Thrombosis (NATA). Available at: http://www. nataonline.com

38. Shields LE, Wiesner S, Fulton J, Pelletreau B. Comprehensive maternal hemorrhage protocols reduce the use of blood products and improve patient safety. Am J Obstet Gynecol. 2015; 212: 272—80.

39. National Blood Authority Australia PBM Guidelines. Available at: http://www.blood.gov.au/pbm-guidelines

40. Munnoz M, Acheson AG, Auerbach M, Besser M, Habler O, Kehlet H et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017; 72: 233—47.

41. Arnold DL, Williams MA, Miller RS, Qiu C, Sorensen TK. Maternal iron deficiency anaemia is associated with an increased risk of abruption placentae — a retrospective case-control study. J Obstet Gynaecol Res. 2009; 35: 446—52.

42. Intraoperative cell salvage education workbook. Edition 1. December 2008.

43. Kozek-Langenecker SA, Ahmed AB, Afshari A, Albaladejo P, Aldecoa C, Barauskas G et al. Management of severe perioperative bleeding. Guidelines from the European Society of Anaesthesiology. First update 2016. Eur J Anaesthesiol. 2017;34:332—95.

44. Villar J, Valladarus Е, Wojdyla D, Zavaleta N, Carroll O, Velazco А et al. WHO 2005 global survey on maternal and perinatal health research group. Caesarean delivery rates and pregnancy outcomes: the 2005 WHO global survey on maternal and perinatal health in Latin America. Lancet. 2006;367:1819—29.

45. McDonnell NJ, Kennedy D, Long LJ, Gallagher-Swann MC, Paech MJ. The development and implementation of an obstetric cell salvage service. Anaesth Intensive Care. 2010; 38: 492—9.

46. Klein AA, Arnold P, Bingham RM, Brohi K, Clark R, Collis R et al. AAGBI guidelines: the use of blood components and their alternatives. Anaesthesia. 2016; 71: 743–7.

47. Engelbrecht S, Wood EM, Cole-Sinclair MF. Clinical transfusion practice update: haemovigilance, complications, patient blood management and national standards. Med J Aust. 2013;199:397—401.

48. Nigam A, Prakash A, Saxena P. Blood transfusion in obstetrics. Kathmandu Univ Med J. 2013;11:355—9.

49. Prick BW, Steegers EA, Jansen AJ, Hop WC, Essink-Bot ML, Peters NC et al. Well being of obstetric patients on minimal blood transfusions (WOMB trial). BMC Pregnancy Childbirth. 2010;16:83.

50. Royal College of Obstetricians and Gynaecologists. Green-top Guideline. Blood Transfusion in Obstetrics. 2015.

51. Milman N. Prepartum anemia: Prevention and treatment. Ann Hematol. 2008;87:949—59.

52. Ekiz C, Agaoglu L, Karakas Z, Gurel N, Yalcin I. The effect of iron deficiency anemia on the function of the immune system. Hematol J. 2005;5:579—83.

53. Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ. Guidelines on the management of massive blood loss. Br J Haematol. 2006;135:634—41.

54. National Clinical Guideline Centre (UK). Blood Transfusion. National Institute for Health and Care Excellence (UK). London. 2015.

55. Beard JL. Why iron deficiency is important in infant development. J Nutr. 2008;138:2534—6.

56. Cogswell ME, Parvanta I, Ickes L, Yip R, Brittenham GM. Iron supplementation during pregnancy, anemia, and birth weight: a randomised controlled trial. Am J Clin Nutr. 2003;78:773—81.

57. You WB, Zahn СМ. Postpartum haemorrhage: abnormally adherent placenta, uterine inversion, and puerperal haematomas. Clin Obstet Gynecol. 2006;49:184—97.

58. Baptista Gonzalez HA, Vidal Gonzalez VM; Mexican College of Obstetrics and Gynecology Specialists. Clinical practice guidelines. Transfusional support and treatment in women with obstetric haemorrhage. Ginecol Obstet Mex. 2009;77:S87—S128.

59. Girard T, Mortl M, Schlembach D. New approaches to obstetric hemorrhage: the postpartum hemorrhage consensus algorithm. Curr Opin Anaesthesiol. 2014;27:267—74.

60. International Federation of Gynecology and Obstetrics. Treatment of postpartum hemorrhage with misoprostol. Int J Gynaecol Obstet. 2012;119:215—6.

61. Kacmar RM, Mhyre JM, Scavone BM, Fuller AJ, Toledo P. The use of postpartum hemorrhage protocols in United States academic obstetric anesthesia units. Anesth Analg. 2014;119:906—10.

62. Lalonde A. International Federation of Gynecology and Obstetrics. Prevention and treatment of postpartum hemorrhage in low-resource settings. Int J Gynaecol Obstet. 2012;117:108—18.

63. Nebout S, Merbai N, Faitot V, Keita H. Management of major postpartum hemorrhage. Presse Med. 2013;43:111—117.

64. WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva: World Health Organization. 2012.

65. Breymann C, Honegger C, Hosli I, Surbek D, Breymann Сh. Diagnosis and treatment of iron-deficiency anaemia in pregnancy and postpartum. Arch Gynecol Obstet. 2017;296:1229—34.

66. Pfenniger A, Schuller C, Christoph P, Surbek D. Safety and efficacy of high-dose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia. J Perinat Med. 2012;40:397—402.

67. Reveiz L, Gyte GML, Cuervo LG, Casasbuenas A. Treatments for irondeficiency anaemia in pregnancy. Cochrane library, 2011. CD003094. pub3.

68. Lyseng-Williamson KA, Keating GM. Ferric caroboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69:739—56.

69. WHO iron deficiency anaemia: assessment, prevention and control. WHO/NHD/01.3, World Health Organization. Geneva, Switzerland. 2001.

70. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System 1993–2005. Public Health Nutr. 2009;12:444—54.

71. Coad J, Conlon C. Iron deficiency in women: assessment, causes and consequences. Current opinion in clinical nutrition and metabolic care. 2011;14:625—34.

72. Pavord S, Myers B, Robinson S, Allard S, Strong J, Oppenheimer C. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2012;156:588—600.

73. Bothwell TH. Iron requirements in pregnancy and strategies to meet them. Am J Clin Nutr. 2000;72:257S—64S.

74. Perez EM, Hendricks MK, Beard JL, Murray-Kolb LE, Berg A, Tomlinson M et al. Mother-infant interactions and infant development are altered by maternal iron deficiency anemia. J Nutrition. 2005;135:850—5.

75. Konovodova EN, Serov VN, Burle VA, Tyutyunnik VL, Kan NE, Sukhich GT. Diagnosis, prophylaxis and treatment of iron-deficiency states in pregnant women and puerperas. Obstetrics and Gynecology. 2012;4/2:3—9 (in Russian).

76. Christoph P, Schuller C, Studer H, Irion O, De Tejada BM, Surbek D. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med. 2012;40:469—74.

77. Gozzard D. When is high-dose intravenous iron repletion needed? Assessing new treatment options. Drug Des Devel Ther. 2011;5:51—60.

78. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199:431—7.

79. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110:267—78.

80. Жетишев РА, Шабалов НП, Иванов ДО, Мызникова ИВ, Петренко ЮВ. Анемии новорожденных: диагностика, профилактика, лечение. Клинические рекомендации (проект). Детская медицина Северо-Запада. 2014;5:4—16.

81. Рагимов АА. Аутодонорство и аутогемотрансфузии. ГЕОТАР-Медиа. Москва. 2011.

82. Титков КВ. Аутотрансфузия эритроцитов пуповинной крови детям с врожденными пороками развития при раннем хирургическом вмешательстве. Анестезиология и реаниматология. 2014;59:38—43.

83. Приказ Министерства здравоохранения России от 02.04.2013 N 183н «Об утверждении правил клинического использования донорской крови и (или) ее компонентов».

84. Быстрых ОА, Федорова ТА, Стрельникова ЕВ. Современные принципы безопасности переливания эритроцитсодержащих компонентов донорской крови. Анестезиология и реаниматология. 2013;6:57—9.

85. Жибурт ЕБ, Попова ВИ, Иванова ИВ, Рейзман ПВ. Скрининг антиэритроцитарных антител и другие практические вопросы иммуносерологии. Трансфузиология. 2004;5:72—9.

86. Минеева НВ. Группы крови человека. Основы иммуногематологии. СПб. 2004. 188 стр. Остальные источники см. в References.

87. References

88. AAP subcommittee on hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114:297—316.

89. New HV, Berryman J, Bolton-Maggs PH, Cantwell C, Chalmers EA, Davies T. et al. Guidelines on transfusion for fetuses, neonates and older children. Br J Haematol. 2016;175:784—828.

90. Thayyil S, Milligan DW. Single versus double volume exchange transfusion in jaundiced newborn infants. Cochrane Database System Rev. 2006;18:CD004592.

91. Smits-Wintjens VE, Rath ME, van Zwet EW, Oepkes D, Brand A et al. Neonatal morbidity after exchange transfusion for red cell alloimmune hemolytic disease. Neonatology. 2013;103:141—7.

92. Girelli G, Antoncecchi S, Casadei AM, Del Vecchio A, Isernia P, Motta M et al. Recommendations for transfusion therapy in neonatology. Blood Transfus. 2015;13:484—97. doi: 10.2450/2015.0113-15

93. De Waal KA, Baerts W, Offringa M. Systematic review of the optimal fluid for dilutional exchange transfusion in neonatal polycythaemia. Arch Dis Child Fetal Neonatal Ed. 2006;91:F7—F10.

94. Bell EF, Strauss RG, Widness JA, Mahoney LT, Mock DM, Seward VJ et al. Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm infants. Pediatrics. 2005;115:1685e91.

95. Kirpalani H, Whyte RK, Andersen C, Asztalos EV, Heddle N, Blajchman MA et al. The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. J Pediatr. 2006;149:301e7.

96. Chen HL, Tseng HI, Lu CC, Yang SN, Fan HC, Yang RC. Effect of blood transfusions on the outcome of very low body weight preterm infants under two different transfusion criteria. Pediatr Neonatol. 2009;50:110e6.

97. Whyte R, Kirpalani H. Low versus high haemoglobin concentration threshold for blood transfusion for preventing morbidity and mortality in very low birth weight infants. Cochrane Database of Systematic Reviews. 2011;11:CD000512.

98. Venkatesh V, Khan R, Curley A, Hopewell S, Doree C, Stanworth S. The safety and efficacy of red cell transfusions in neonates: a systematic review of randomized controlled trials. Br J Haematol. 2012;158:370—85.

99. Ibrahim M, Ho SK, Yeo CL. Restrictive versus liberal red blood cell transfusion thresholds in very low birth weight infants: a systematic review and meta-analysis. J Paediatr Child Health. 2014;50:122—30.

100. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R et al. European Consensus Guidelines on the management of respiratory distress syndrome — 2016 update. Neonatology. 2017;111:107—25. doi: 10.1159/000448985

101. Whyte RK, Jefferies AL, Canadian Paediatric Society, Fetus and Newborn Committee. Red blood cell transfusion in newborn infants. Paediatr Child Health. 2014;19:213—22.

102. Ohls RK. Red blood cell transfusions in the newborn infants. Paediatr Child Health. 2014;19:213—7.

103. Mimica AF, dos Santos AM, da Cunha DH, Guinsburg R, Bordin JO, Chiba A et al. A very strict guideline reduces the number of erythrocyte transfusions in preterm infants. Vox Sang. 2008;95:106—1. doi: 10.1111/j.1423-0410.2008.01072.x

104. Ross MP, Christensen RD, Rothstein G, Koenig JM, Simmons MA, Noble NA et al. A randomized trial to develop criteria for administering erythrocyte transfusions to anemic preterm infants 1 to 3 months of age. J Perinatology. 1989;9:246—53.

105. Gibson BE, Todd A, Roberts I, Pamphilon D, Rodeck C, Bolton-Maggs P et al. Transfusion guidelines for neonates and older children. Br J Haematol. 2004;124:433—53.

106. Widness JA. Treatment and prevention of neonatal anemia. Neoreviews. 2008;9:526—33.

107. Strauss RG. Anaemia of prematurity: pathophysiology and treatment. Blood Rev. 2010;24:221e5.

108. Alverson DC, Isken VH, Cohen RS. Effect of booster blood transfusions on oxygen utilization in infants with bronchopulmonary dysplasia. Journal of Pediatrics. 1988;113:722—6.

109. Sawyer AA, Wise L, Ghosh S, Bhatia J, Stansfield BK. Comparison of transfusion thresholds during neonatal extracorporeal membrane oxygenation. Transfusion. 2017;57:2115—20.

110. Kirpalani H. The Transfusion of Premature trial (TOP): Does a liberal red blood cell transfusion strategy improve neurologically-intact survival of extremely-low-birth-weight infants as compared to a restrictive strategy? https://ichgcp.net/clinical-trials-registry/NCT01702805

111. ETTNO Investigators. The ‘Effects of transfusion thresholds on neurocognitive outcome of extremely low birth-weight infants (ETTNO)’ study: background, aims, and study protocol. Neonatology. 2012;101:301—5.

112. National comparative audit of blood transfusion. National comparative audit of the use of red cells in neonates and children 2010. http://hospital.blood.co.uk/library/pdf/NCA_red_cells_neonates_ children.pdf.

113. Venkatesh V, Khan R, Curley A, New H, Stanworth S. How we decide when a neonate needs a transfusion. Br J Haematol. 2013; 160:421—33.

114. Brusseau R, McCann M. Anaesthesia for urgent and emergency surgery. Early Hum Dev. 2010;86:703—14.

115. Lindern J, LoprioreE. Management and prevention of neonatal anemia: current evidence and guidelines. Expert Rev Hematol. 2014;7:195—202.

116. Hematology, immunology and infectious disease: neonatology questions and controversies. Eds R. Ohls, M. C. Yoder. Elsevier. 2008. 294 p.

117. Zhetishev RA, Shabalov NP, Ivanov DO, Myznikova IV, Petrenko YuV. Neonatal anemia, diagnosis, prevention, treatment. Clinical practice guidelines (draft). North-West Pediatric Medicine. 2014;5:4—16 (in Russian).

118. Hosono S. Autologous cord blood transfusion in an infant with a huge sacrococcygeal teratoma. J Perinat Med. 2004;32:187—9.

119. Imura K. The usefulness of cord blood harvesting autotransfusion in surgical neonates with prenatal diagnosis of congenital anomalies. J Pediatr Surg. 2001;36:851—4.

120. Taguchi T. The efficacy of autologous cord-blood transfusions in neonatal surgical patients. J Ped Surg. 2003;38:604—7.

121. Ragimov AA. Autodonation and autohemotransfusions. Geotar-Media. Moscow. 2011 (in Russian).

122. Titkov KV. Autotransfusion of cord blood erythrocytes in newborns with malformation requiring early surgical intervention. Anesteziologiya i Reanimatologiya. 2014;59:38—43 (in Russian).

123. The order No. 183n “On validation of regulations of clinical use of donor blood and(or) Its components” of the Ministry of Health of Russia. (in Russian)

124. Bystrykh OA, Feodorova TA, Strelnikova EV. Recent principles of erythrocytes-containing donor blood components transfusion. Anesteziologiya i Reanimatologiya. 2013;6:57—9 (in Russian).

125. Daniels G, Bromilow I. Essential guide to blood groups. John Wiley & Sons, Ltd. 2014.

126. Bennardello F, Coluzzi S, Curciarello G, Todros T, Villa S. Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn. Blood Transfus. 2015;13:109—34.

127. Zhiburt EB, Popova VI, Ivanova IV, Reyzman PV. Screening of anti-erythrocytes auto-antibodies and the other practical questions of immunoserology. Transfusiology. 2004;5:72—9 (in Russian).

128. Mineeva NV. Human blood groups. Basics of immunohematology. Saint Petersburg. 2004. 188 p (in Russian).

129. Edward CC, Wong MD. Blood banking/immunohematology special relevance to pediatric patients. Pediatr Clin North Am. 2013;60:1541—68. doi: 10.1016/j.pcl.2013.08.005.

130. Neonatal transfusion guidance. AABB. Bethesda. 2012.

131. Keir AK, Wilkinson D, Andersen C, Stark MJ. Washed versus unwashed red blood cells for transfusion for the prevention of morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews. 2016;19:CD011484.

132. Hauck- Dlimi B, Braun T, Eckstein R, Strobel J, Zimmermann R. Influence of early irradiation on in vitro red blood cell (RBC) storage variables of leucoreduced RBCs in additive solution SAG-M. Vox Sang. 2016;110:362—8.

133. Patel RM, Christensen RD, Maheshwari A. Anemia, red blood cell transfusions, and necrotizing enterocolitis. Seminars in Pediatric Surgery. 2018;27:47—51.

134. Amin SC, Remon JI, Subbarao GC, Maheshwari A. Association between red cell transfusions and necrotizing enterocolitis. J Matern Fetal Neonatal Med. 2012;25:85—9.

135. Faraday C, Hamad S, Jones KD, Sim K, Cherian S, James A et al. Characteristics and incidence of transfusion-associated necrotizing enterocolitis in the UK. J Matern Fetal Neonatal Med. 2018;1:1—6.

136. Trevino-Baez JD, Briones-Lara E, Alamillo-Velazquez J, MartinezMoreno MI. Multiple red blood cell transfusions and iron overload in very low birthweight infants. Vox Sang. 2017;112:453—8.

137. Горбашко АИ. Диагностика и лечение кровопотери: руководство для врачей. Медицина. Ленинград. 1982.

138. Вагнер ЕА, Тавровский ВМ. Трансфузионная терапия при острой кровопотере. Медицина. Москва. 1977.

139. Мазурок ВА. Очевидные и спорные вопросы восполнения острой массивной кровопотери. Хирургическая практика. 2013;4:11—19.

140. Остальные источники см. в References.

141. References

142. Stainsby D, MacLennan S., Hamilton PJ. Management of massive blood loss: a template guideline. Br J Anaesth. 2000;85:487—91.

143. Hardy JF, De Moerloose P, Samama M. Groupe d’Interet en Hemostase Perioperatoire. Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anaesth. 2004;51:293— 310. doi: 10.1007/BF03018233

144. Hayter MA, Pavenski K, Baker J. Massive transfusion in the trauma patient: continuing professional development. Can J Anaesth. 2012;59:1130—45. doi: 10.1007/s12630-012-9795-4

145. National Blood Authority. Patient blood management guidelines: module 1 — critical bleeding/massive transfusion. NBA. Canberra, Australia. 2011.

146. Gorbashko AI. Diagnosis and treatment of the blood loss: Manual. Medicine. Leningrad. 1982 (in Russian).

147. Vagner EA, Tavrovskiy VM. Transfusion therapy for acute blood loss. Medicine. Moscow. 1977 (in Russian).

148. Mazurok VA. Obvious and controversial issues of resuscitation of acute massive blood loss. Surgical practice. 2013;4:11—19 (in Russian).

149. Hardy J-F, de Moerloose P, Samama CM, Members of the Groupe d’Interet en Hemostase Perioperatoire. Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anaesth. 2006;53:S40—58.

150. Uijttewaal WS, Nijhof EJ, Bronkhorst PJ, Den Hartog E, Heethaar RM. Near-wall excess of platelets induced by lateral migration of erythrocytes in flowing blood. Am J Physiol. 1993;264:H1239—44.

151. Sagesaka T. Influence of red blood cell concentration on the initiation time of blood coagulation: risk of thrombus formation by hemoconcentration. Clin Hemorheol Microcirc. 2004;31:243—9.

152. Peyrou V, Lormeau JC, Herault JP, Gaich C, Pfliegger AM, Herbert JM. Contribution of erythrocytes to thrombin generation in whole blood. Thromb Haemost. 1999;81:400—6.

153. Litvinov RI, Weisel JW. Role of red blood cells in haemostasis and thrombosis. ISBT Sci Ser. 2017;12:176—183. doi: 10.1111/voxs.12331

154. Bombeli T, Spahn DR. Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage. Br J Anaesth. 2004;93:275—87.

155. Iwata H, Kaibara M. Activation of factor IX by erythrocyte membranes causes intrinsic coagulation. Blood Coagul Fibrinolysis. 2002;13:489—96.

156. Iselin BM, Willimann PF, Seifert B, Casutt M, Bombeli T, Zalunardo MP et al. Isolated reduction of haematocrit does not compromise in vitro blood coagulation. Br J Anaesth. 2001;87:246—9.

157. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, FernandezMondejar E et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care. 2016;20:100. doi: 10.1186/s13054-016-1265-x

158. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, FernandezMondejar E et al. Management of bleeding following major trauma: a European guideline. Crit Care. 2010;14:R52. doi: 10.1186/cc8943

159. Snyder HS. Significance of the initial spun hematocrit in trauma patients. Am J Emerg Med. 1998;16:150—3.

160. Paradis NA, Balter S, Davison CM, Simon G, Rose M. Hematocrit as a predictor of significant injury after penetrating trauma. Am J Emerg Med. 1997;15:224—8.

161. Zehtabchi S, Sinert R, Goldman M, Kapitanyan R, Ballas J. Diagnostic performance of serial haematocrit measurements in identifying major injury in adult trauma patients. Injury. 2006;37:46—52.

162. Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G. Recommendations for the transfusion of red blood cells. Blood Transfus. 2009;7:49—64.

163. Lieberman JA, Weiskopf RB, Kelley SD, Feiner J, Noorani M, Leung J et al. Critical oxygen delivery in conscious humans is less than 7.3 ml O2 x kg(-1) x min(-1). Anesthesiology. 2000;92:407—13.

164. Hajjar LA, Vincent J-L, Galas FRBG, Nakamura RE, Silva CMP, Santos MH et al. Transfusion requirements after cardiac surgery. JAMA. 2010;304:1559.

165. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E et al. The CRIT study: Anemia and blood transfusion in the critically ill — Current clinical practice in the United States. Crit Care Med. 2004;32:39—52.

166. Vincent JL, Sakr Y, Sprung C, Harboe S, Damas P. Sepsis Occurrence in Acutely Ill Patients (SOAP) Investigators. Are blood transfusions associated with greater mortality rates? Results of the Sepsis Occurrence in Acutely Ill Patients study. Anesthesiology. 2008;108:31—9.

167. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340:409—17

168. Villanueva C, Colomo A, Bosch A, Concepcion M, HernandezGea V, Aracil C et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368:11—21.

169. Plumb JO, Grocott MP. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med. 2015;373:192—3.

170. Weinberg JA, McGwin G, Marques MB, Cherry SA, Reiff DA, Kerby JD et al. Transfusions in the less severely injured: does age of transfused blood affect outcomes? J Trauma. 2008;65:794—8.

171. Croce MA, Tolley EA, Claridge JA, Fabian TC. Transfusions result in pulmonary morbidity and death after a moderate degree of injury. J Trauma. 2005;59:19—24.

172. Claridge JA, Sawyer RG, Schulman AM, McLemore EC, Young JS. Blood transfusions correlate with infections in trauma patients in a dosedependent manner. Am Surg. 2002;68:566—72.

173. Chaiwat O, Lang JD, Vavilala MS, Wang J, MacKenzie EJ, Jurkovich GJ et al. Early packed red blood cell transfusion and acute respiratory distress syndrome after trauma. Anesthesiology. 2009;110:351—60.

174. Alexander J, Cifu AS. Transfusion of red blood cells. JAMA. 2016;316:2038. doi: 10.1001/jama.2016.12870

175. Carson JL, Grossman BJ, Kleinman S., Tinmouth AT, Marques MB, Fung MK et al. Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med. 2012;157:49—58.

176. Nakamura RE, Vincent JL, Fukushima JT, de Almeida JP, Franco RA, Lee Park C et al. A liberal strategy of red blood cell transfusion reduces cardiogenic shock in elderly patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2015;150:1314—20.

177. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: A systematic review of the literature. Crit Care Med. 2008;36:2667—74.

178. Dente CJ, Shaz BH, Nicholas JM, Harris RS, Wyrzykowski AD, Patel S et al. Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian level I trauma center. J Trauma. 2009;66:1616—24. doi: 10.1097/TA.0b013e3181a59ad5

179. Holcomb JB, Wade CE, Michalek JE, Chisholm GB, Zarzabal LA, Schreiber MA et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg. 2008;248:447—58. doi: 10.1097/SLA.0b013e318185a9ad

180. Maegele M, Lefering R, Paffrath T, Tjardes T, Simanski C, Bouillon B; Working Group on Polytrauma of the German Society of Trauma Surgery (DGU). Red-blood-cell to plasma ratios transfused during massive transfusion are associated with mortality in severe multiple injury: a retrospective analysis from the Trauma Registry of the Deutsche Gesellschaft fur Unfallchirurgie. Vox Sang. 2008;95:112—9.

181. Shaz BH, Dente CJ, Nicholas J, MacLeod JB, Young AN, Easley K et al. Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. Transfusion. 2010;50:493—500.

182. Sperry JL, Ochoa JB, Gunn SR, Alarcon LH, Minei JP, Cuschieri J et al. An FFP:PRBC transfusion ratio >/=1:1.5 is associated with a lower risk of mortality after massive transfusion. J Trauma. 2008;65:986—93.

183. Stinger HK, Spinella PC, Perkins JG, Grathwohl KW, Salinas J, Martini WZ et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma. 2008;64:S79—85.

184. Cotton BA, Dossett LA, Au BK, Nunez TC, Robertson AM, Young PP. Room for (performance) improvement: provider-related factors associated with poor outcomes in massive transfusion. J Trauma. 2009;67:1004—12.

185. Gunter OL Jr, Au BK, Isbell JM, Mowery NT, Young PP, Cotton BA. Optimizing outcomes in damage control resuscitation: identifying blood product ratios associated with improved survival. J Trauma. 2008;65:527—34.

186. Leahy MF, Trentino KM, May C, Swain SG, Chuah H, Farmer SL. Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. Transfusion. 2017;57:2189—96.

187. DeZern AE, Williams K, Zahurak M, Hand W, Stephens RS, King KE et al. Red blood cell transfusion triggers in acute leukemia: a randomized pilot study. Transfusion. 2016;56:1750—7.

188. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK et al. Clinical practice guidelines from the AABB: Red blood cell transfusion thresholds and storage. JAMA. 2016;316:2025—35.

189. Fan L, Fu D, Zhang J, Huang H, Wang Q, Ye Y et al. Prognostic significance of blood transfusion in newly diagnosed multiple myeloma patients without autologous hematopoietic stem cell transplantation. Biomed Res Int. 2017;2017:5462087. doi:10.1155/2017/5462087

190. Holst LB, Petersen MW, Haase N, Perner A, Wetterslev J. Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis. BMJ. 2015;350:h1354.

191. Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125:3246—52.

192. Hoeks MPA, Kranenburg FJ, Middelburg RA, van Kraaij MG, Zwaginga JJ. Impact of red blood cell transfusion strategies in haematooncological patients: a systematic review and meta-analysis. Brit J Haematol. 2017;178:137—51.

193. British Committee for Standards in Haematology (BCSH). Доступно в интернете по адресу: www.londoncanceralliance.nhs.uk. По состоянию на 22 сентября 2017 г.

194. Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E et al. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. Cancer. 2012;118:848—55.

195. Diehl L, Ketchum L. Autoimmune disease and chronic lymphocytic leukemia: Autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol. 1998;25:80—97.

196. Bennett JM. MDS Foundation’s Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83:858—61.

197. Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Angelucci E, Van Lint MTF et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica. 2010;95:476—84.

198. Gajewski JL, Johnson VV, Sandler SG, Sayegh A, Klumpp TR. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood. 2008;112:3036—47.

199. Petz LD. A physician’s guide to transfusion in autoimmune hemolytic anemia. Brit J Haematol. 2004;124:712—6.

200. Petz LD. Cold antibody autoimmune hemolytic anemia. Blood Review. 2008;22:1—15.

201. Shirey RS, Parwani AV, Tanz WS, Ness PM, King KE. Prophylactic antigen-matched donor blood for patients with warm autoantibodies: an algorithm for transfusion management. Transfusion. 2002;42:1435—41.

202. Petz LD. “Least incompatible” units for transfusion in autoimmune hemolytic anemia: should we eliminate this meaningless term? A commentary for clinicians and transfusion medicine professionals. Transfusion. 2003;43:1503—7.

203. Buetens OW, Ness PM. Red cell transfusion in autoimmune hemolytic anemia. Current Opinion in Hematology. 2003;10:429—33.

204. Packman CH. Hemolytic anemia due to warm autoantibodies. Blood Rev. 2008;22:17—31.

205. Ness PM. How do I encourage clinicians to transfuse mismatched blood to patients with autoimmune hemolytic anemia in urgent situations? Transfusion. 2006;46:1859—62.

206. Yuerek S, Mayer B, Almahallawi M, Pruss A, Salama A. Precautions surrounding blood transfusion in autoimmune hemolytic anemias are overestimated. Blood Transfusion. 2015;13:616—21.

207. Shander A, Javidroozi M, Naqvi S, Aregbeyen O, Caylan M, Demir S et al. An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion. Transfusion. 2014;54:2688—95.

208. Douglas WD, Uffort E, Denning D. Transfusion and management of surgical patients with hematologic disorders. Surg Clin N Am. 2014. 95;2:367—77. http://dx.doi.org/10.1016/j.suc.2014.11.004

209. Davis BA, Allard S, Qureshi A,Porter JB, Pancham S, Win N et al. Guidelines on red cell transfusion in sickle cell disease. Part II: indications for transfusion. Br J Haematol. 2017;176:192—209. doi: 10.1111/ bjh.14383

210. Балашов ДН, Трахтман ПЕ. Особенности проведения трансфузионной терапии у пациентов после трансплантации гемопоэтических стволовых клеток. Обзор литературы. Онкогематология. 2013;13:42—47.

211. Остальные источники см. в References.

212. References

213. Gorlin JB, Minz PD. Transfusion-associated graft-vs-host disease. In: Mintz PD editor. Transfusion Therapy: Clinical Principles and Practice. Bethesda, MD: AABB. 2005. p. 579—96.

214. Anderson KS, Weinstein HJ. Transfusion-associated graft versus host disease. N Engl J Med. 1990;323:315—21.

215. Mandusio P. Transfusion-associated graft versus host disease: A concise review. Hematol Rep. 2018:10:7724. doi: 10.4081/hr.2018.7724

216. Agbaht K, Altintas ND, Topeli A, Gokoz O, Ozcebe O. Transfusionassociated graft versus host disease in immunocompetent patients: case series and review of the literature. Transfusion. 2007;47:1405—11.

217. Topics in transfusion medicine. Guidelines. Irradiated blood products. Leucocyte depletion of blood and blood components. Australasian Society of Blood Transfusion Inc. October 1996. Available at: http://www.anzsbt. org.au/publications/documents/ 1996; 3_2.pdf

218. British Committee for Standards in Haematology Blood Transfusion Task Force. Guidelines on the clinical use of leukocyte-depleted blood components. Transfus Med. 1998;8:59—71.

219. Ratko TA, Cummings JP, Oberman HA, Crookston KP, DeChristopher PJ, Eastlund DT et al. Evidence-based recommendations for the use of WBCreduced cellular blood components. Transfusion. 2001;41:1310—9.

220. De Graan-Hentzen YC, Gratama JW, Mudde GC, Verdonck LF, Houbiers JG, Brand A et al. Prevention of primary cytomegalovirus infection of patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion. 1989;1:1228—31.

221. Van Prooijen HC, Visser JJ, van Oostendorp WR, de Gast GC, Verdonck LF. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br J Haematol. 1994;87:144—7.

222. Ziemann M, Thiele T. Transfusion-transmitted CMV infection — current knowledge and future perspectives. Transfus Med. 2017;27:238—48. doi: 10.11112/tme.12437

223. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G et al. A compassion of filtered leucocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86:3598—603.

224. British Committee for Standards in Haematology Blood Transfusion Task Force. Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. Transfus Med. 1996;6:261—71.

225. Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016;10:CD002042. doi: 10.1002/14651858.CD002042.pub4

226. Hebert PC, Wells G, Martin C, Tweeddale M, Marshall J, Blajchman M. Variation in red cell transfusion practice in the intensive care unit: a multicentre cohort study. Crit Care. 1999;3:57—63. doi: 10.1186/cc310

227. Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. The Lancet. 2007;370:415—26. doi: http://dx.doi.org/10.1016/ S0140-6736(07)61197-0

228. Wallis JP. Red cell transfusion triggers. Transfus Apher Sci. 2008;39:151— 4. doi: 10.1016/j.transci.2008.06.004

229. Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G. Recommendations for the transfusion of red blood cells. Blood Transfus. 2009;7:49—64. doi:10.2450/2008.0020-08

230. Balashov DN, Trakhtman PE. Features of transfusion therapy in patients undergoing hematopoietic stem cell transplantation. Review of the literature. Oncohematology. 2013;13:42—7.

231. Small M, Lowe GD, Cameron E, Forbes CD. Contribution of the haematocrit to the bleeding time. Haemostasis. 1983;13:379—84.

232. Escolar G, Garrido M, Mazzara R, Castillo R, Ordinas A. Experimental basis for the use of red cell transfusion in the management of anemicthrombocytopenic patients. Transfusion. 1988;28:406—11.

233. Burns ER, Lawrence C. Bleeding time. A guide to its diagnostic and clinical utility. Arch Pathol Lab Med. 1989;113:1219—24.

234. Ho CH. The hemostatic effect of adequate red cell transfusion in patients with anemia and thrombocytopenia. Transfusion. 1996;36:290.

235. Crowley JP, Metzger JB, Valeri CR. The volume of blood shed during the bleeding time correlates with the peripheral venous hematocrit. Am J Clin Pathol. 1997;108:579—84.

236. Valeri CR, Cassidy G, Pivacek LE, Ragno G, Lieberthal W, Crowley JP et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion. 2001;41:977—83.

237. British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122:10—23.

238. Eugster M, Reinhart WH. The influence of the haematocrit on primary haemostasis in vitro. Thromb Haemost. 2005;94:1213—8.

239. Webert KE, Sigouin CS, Cook RJ. Insights into the risk of bleeding in thrombocytopenic patients with acute leukaemia. Transfusion. 2005;45:S33.

240. Webert K, Cook RJ, Sigouin CS, Rebulla P, Heddle NM. The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica. 2006;91:1530—7.

241. Kopko PM. Transfusion support for ABO-incompatible progenitor cell transplantation. Transfus Med Hemother. 2016;43:13—8. doi: 10.1159/000441612

242. Worel N. ABO-mismatched allogeneic hematopoietic stem cell transplantation. Transfus Med Hemother. 2016;43:3—12. doi: 10.1159/000441507

243. Working Party of the British Committee for Standarts in Haematology Blood Transfusion Task Forse. Guedelines for compatibility procedures in blood transfusions laboratories. Transfus Med. 2004;14:59—73.

244. Rowley CD, Donato ML, Bhattacharyya P. Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2011;46:1167—85.

245. Booth GS, Gehrie EA, Bolan CD, Savani BN. Clinical guide to ABOincompatible allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:1152—8. doi: 10.1016/j.bbmt.2013.03.018

246. Nickel RS, Qayed M, Worthington-White D, Stowell SR, Chiang KY. Infusion hemolysis after pediatric major ABO-mismatched bone marrow transplant: Comparison of two red blood cell depletion techniques. Pediatr Blood Cancer. 2018;65. doi: 10.1002/pbc.26883

247. Gutierrez-Aguirre CH, Gomez-De-Leon A, Alatorre-Ricardo J, Cantu-Rodriguez OG, Gonzalez-Llano O et al. Allogeneic peripheral blood stem cell transplantation using reduced-intensity conditioning in an outpatient setting in ABO-incompatible patients: are survival and graft-versus-host disease different? Transfusion. 2014;54:1269—77. doi: 10.1111/trf.12466

248. Canaani J, Savani BN, Labopin M, Mohty M, Nagler A et al. ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. Am J Hematol. 2017;92:789—96. doi: 10.1002/ajh.24771

249. Docherty AB, O’Donnell R, Brunskill S, Trivella M, Doree C, Holst L et al. Effect of restrictive versus liberal transfusion strategies on outcomes in patients with cardiovascular disease in a non-cardiac surgery setting: systematic review and meta-analysis. BMJ. 2016;352:i1351.

250. Ripolles Melchor J, Casans Frances R, Espinosa A, Martinez Hurtado E, Navarro Perez R, Abad Gurumeta A et al.; EAR Group Anesthesia Evidence Review. Restrictive versus liberal transfusion strategy for red blood cell transfusion in critically ill patients and in patients with acute coronary syndrome: a systematic review, meta-analysis and trial sequential analysis. Minerva Anestesiologica. 2016;82:582—98.

251. Docherty AB, Walsh TS. Anemia and blood transfusion in the critically ill patient with cardiovascular disease. Crit Care. 2017;21:61.

252. Holst LB, Petersen MW, Haase N, Perner A, Wetterslev J. Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis. BMJ. 2015;350:h1354.

253. Carson JL, Brooks MM, Abbott JD, Chaitman B, Kelsey SF, Triulzi DJ et al. Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J. 2013;165:964—1.

254. Kocsi S, Demeter G, Fogas J, Erces D, Kaszaki J, Molnar Z. Central venous oxygen saturation is a good indicator of altered oxygen balance in isovolemic anemia. Acta Anaesthesiol Scand. 2012;56:291—7

255. Kocsi S, Tanczos K, Molnar Z. ScvO2 as an alternative transfusion trigger / In: Juffermans N, Walsh T (eds). Transfusion in the intensive care unit. Springer. Cham. 2015.

256. Nemeth M, Tanczos K, Demeter G, Erces D, Kaszaki J, Mikor A et al. Central venous oxygen saturation and carbon dioxide gap as resuscitation targets in a hemorrhagic shock. Acta Anaesthesiol Scand. 2014;58:611—9.

257. Nasser B, Tageldein M, Al Mesned A, Kabbani M. Effects of blood transfusion on oxygen extraction ratio and central venous saturation in children after cardiac surgery. Ann Saudi Med. 2017;37:31—7.

258. Creteur J, Neves AP, Vincent JL. Near-infrared spectroscopy technique to evaluate the effects of red blood cell transfusion on tissue oxygenation. Crit Care. 2009;13 Suppl 5:S11.

259. Hovaguimian F, Myles PS. Restrictive versus liberal transfusion strategy in the perioperative and acute care settings: a context-specific systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2016;125:46—61.

260. Liumbruno GM, Vaglio S, Biancofiore G, Marano G, Mengoli C, Franchini M. Transfusion thresholds and beyond. Blood Transfus. 2016;4:123—5.

261. Fominskiy E, Putzu A, Monaco F, Scandroglio AM, Karaskov A, Galas FR et al. Liberal transfusion strategy improves survival in perioperative but not in critically ill patients. A meta-analysis of randomised trials. Br J Anaesth. 2015;115:511—9.

262. Nakamura RE, Vincent JL, Fukushima JT, de Almeida JP, Franco RA, Lee Park C et al. A liberal strategy of red blood cell transfusion reduces cardiogenic shock in elderly patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2015;150:1314—20.

263. Redlin M, Kukucka M, Boettcher W., Schoenfeld H, Huebler M, Kuppe H et al. Blood transfusion determines postoperative morbidity in pediatric cardiac surgery applying a comprehensive blood-sparing approach. J Thorac Cardiovasc Surg. 2013;146:537—42.

264. Khan Z, Natarajan G, Sallaam S, Bondarenko I, Walters HL, Delius R et al. Association between anemia and packed cell transfusion and outcomes of ventricular septal defect and atrioventricular canal repair in children. Pediatr Cardiol. 2014;35:471—8.

265. De Gast-Bakker DH, de Wilde RB, Hazekamp MG, Sojak V, Zwaginga JJ, Wolterbeek R et al. Safety and effects of two red blood cell transfusion strategies in pediatric cardiac surgery patients: a randomized controlled trial. Intensive Care Med. 2013;39:2011—9.

266. Cholette JM, Swartz MF, Rubenstein J, Henrichs KF, Wang H, Powers KS et al. Outcomes using a conservative versus liberal red blood cell transfusion strategy in infants requiring cardiac operation. Ann Thorac Surg. 2017;103:206—14.

267. Dasgupta R, Parsons A, McClelland S, Morgan E, Robertson MJ, Noel TR et al. Association of haematocrit and red blood cell transfusion with outcomes in infants with shunt-dependent pulmonary blood flow and univentricular physiology. Blood Transfus. 2015;13:417—22.

268. Cholette JM, Rubenstein JS, Alfieris GM, Powers KS, Eaton M, Lerner NB. Children with single-ventricle physiology do not benefit from higher hemoglobin levels post cavopulmonary connection: results of a prospective, randomized, controlled trial of a restrictive versus liberal red-cell transfusion strategy. Pediatr Crit Care Med. 2011;12:39—45.

269. Gupta P, King C, Benjamin L, Goodhart T, Robertson MJ, Gossett JM et al. Association of hematocrit and red blood cell transfusion with outcomes in infants undergoing Norwood operation. Pediatr Cardiol. 2015;36:1212—8.

270. Blackwood J, Joffe AR, Robertson CM, Dinu IA, Alton G, Penner K et al. Western Canadian Complex Pediatric Therapies Follow-up Group. Association of hemoglobin and transfusion with outcome after operations for hypoplastic left heart. Ann Thorac Surg. 2010;89:1378—84.

271. Anderson BR, Blancha VL, Duchon JM, Chai PJ, Kalfa D, Bacha EA et al. The effects of postoperative hematocrit on shunt occlusion for neonates undergoing single ventricle palliation. J Thorac Cardiovasc Surg. 2017;153:947—55.

272. Connolly ES Jr., Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:1711—37. doi:10.1161/STR.0b013e3182587839

273. Diringer MN, Bleck TP, Claude Hemphill J3rd, Menon D, Shutter L, Vespa P et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15:211—40. doi:10.1007/s12028-011-9605-9

274. Bratton SL, Chestnut RM, Ghajar J, McConnell Hammond FF, Harris OA, Hartl R et al. Guidelines for the management of severe traumatic brain injury. J Neurotrauma. 2007;24:S1—106.

275. Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016;12;10:CD002042.

276. Desjardins P, Turgeon AF, Tremblay MH, Lauzier F, Zarychanski R, Boutin A et al. Hemoglobin levels and transfusions in neurocritically ill patients: a systematic review of comparative studies. Crit Care. 2012;16:R54. doi:10.1186/cc11293

277. Oddo M, Milby A, Chen I, Frangos S, MacMurtrie E, Maloney-Wilensky E et al. Hemoglobin concentration and cerebral metabolism in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2009;40:1275—81. doi:10.1161/STROKEAHA.108.527911

278. Kurtz P, Helbok R, Claassen J, Schmidt JM, Fernandez L, Stuart RM et al. The effect of packed red blood cell transfusion on cerebral oxygenation and metabolism after subarachnoid hemorrhage. Neurocrit Care. 2016;24:118—21. doi: 10.1007/s12028-015-0180-3

279. Dhar R, Scalfani MT, Zazulia AR, Videen TO, Derdeyn CP, Diringer MN. Comparison of induced hypertension, fluid bolus, and blood transfusion to augment cerebral oxygen delivery after subarachnoid hemorrhage. J Neurosurg. 2012;116:648—56. doi: 10.3171/2011.9.JNS11691

280. Robertson CS, Hannay HJ, Yamal JM, Gopinath S, Goodman JC, Tilley BC et al. Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. JAMA. 2014;312:36—47. doi:10.1001/jama.2014.6490

281. Vedantam A, Yamal JM, Rubin ML, Robertson CS, Gopinath SP. Progressive hemorrhagic injury after severe traumatic brain injury: effect of hemoglobin transfusion thresholds. J Neurosurg. 2016;125:1229—34.

282. Yamal JM, Rubin ML, Benoit JS, Tilley BC, Gopinath S, Hannay HJ et al. Effect of hemoglobin transfusion threshold on cerebral hemodynamics and oxygenation. J Neurotrauma. 2015;32:1239—45. doi: 10.1089/ neu.2014.3752

283. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA. 1993;269:3024—9.

284. Morisaki H, Sibbald WJ. Tissue oxygen delivery and the microcirculation. Crit Care Clin. 2004;20:213—23.

285. Zallen G, Offner PJ, Moore EE, Blackwell J, Ciesla DJ, Gabriel J et al. Age of transfused blood is an independent risk factor for postinjury multiple organ failure. Am J Surg. 1999;178:570—2.

286. Шило ВЮ, Добронравов ВА, Земченков АЮ, Гуревич КЯ, Лысенко ЛВ, Ермоленко ВМ и др. Российские национальные рекомендации по диагностике и лечению анемии при хронической болезни почек. Нефрология и диализ. 2016;18:19—34.

287. Остальные источники см. в References.

288. References

289. Shilo VYu, Zemchenkov AYu, Gurevich KYa, Dobronravov VA, Lysenko LV, Ermolenko VM et al. Russian national clinical recommendations for diagnosis and treatment of anemia in chronic kidney disease. Nephrology and dialysis. 2016;18:19—34.

290. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631—4. doi: 10.1681/ASN.2011111078

291. Hauber B, Caloyeras J, Posner J, Brommage D, Tzivelekis S, Pollock A. Hemodialysis patients preferences for the management of anemia. BMC Nephrol. 2017;18:253. doi: 10.1186/s12882-017-0664-9

292. Obrador GT, Macdougall IC. Effect of red cell transfusions on future kidney transplantation. Сlin J Am Soc Nephrol. 2013;8:852—60. doi: 10.2215/CJN.00020112

293. Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol. 2017;18:345. doi: 10.1186/s12882-017-0688-1

294. Drueke TB, Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int. 2012;82:952— 60. doi: 10.1038/ki.2012.270

295. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288:1499—507.

296. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham EM et al. The CRIT study: anemia and blood transfusion in the critically ill — current clinical practice in the United States. Crit Care Med. 2004;32:39—52.

297. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340:409—417.

298. Holst LB, Haase N, Wetterslev J, Wernerman J, Guttormsen AB, Karlsson S et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014;371:1381—91. doi: 10.1056/NEJMoa1406617

299. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA. 1993;269:3024—9.

300. Lorente JA, Landin L, De Pablo R, Renes E, Rodriguez-Diaz R, Liste D. Effects of blood transfusion on oxygen transport variables in severe sepsis. Crit Care Med. 1993;21:1312—8.

301. Fernandes CJ Jr., Akamine N, De Marco FV, De Souza JA, Lagudis S, Knobel E. Red blood cell transfusion does not increase oxygen consumption in critically ill septic patients. Crit Care. 2001;5:362—7.

302. Dellinger R, Levy M, Rhodes A, Annane D, Gerlach H, Opal S et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580—637. doi:10.1097/CCM.0b013e31827e83af